• Home
  • Top News
  • World
  • Economy
  • science
  • Technology
  • sport
  • entertainment
  • Contact Form
Sunday, May 29, 2022
  • Login
No Result
View All Result
NEWSLETTER
BOB fm
No Result
View All Result
BOB fm
No Result
View All Result
Home science

CureVac Failed: What’s Wrong With Bill Gates’ Vaccine?

by Ursula Curtis
June 20, 2021
in science
0
CureVac Failed: What's Wrong With Bill Gates' Vaccine?
0
SHARES
232
VIEWS
Share on FacebookShare on Twitter

Last Thursday (17) it was announced that the immunizing agent developed by German biotechnology company CureVac, which uses the same technology as Moderna and Pfizer, had failed in the third and final stage of testing. The effectiveness of the COVID-19 vaccine was only 47%. But, after all, what went wrong?

According to a report in the scientific journal Science, the company blames the rapid change in the pandemic virus, but outside researchers blame the vaccine project itself. It turns out that the immune system relies on the competitors’ new mRNA technology, which was 90% effective in their tests.

The company’s CEO announced that several variants of SARS-CoV-2 now circulating may explain the disappointing results, as the vaccine’s mRNA was designed for a version dominant among viruses early in the pandemic, but evolved through multiple mutations.

Experimental scientists sequenced the virus in 124 participants and found 13 different species. Only 1% of those infected had a ‘copy’ of SARS-CoV-2 whose elevated protein matches the mRNA used in the vaccine.

(Photo: Rawpixel)

But outside researchers do not believe that the variants fully explain the poor performance of the vaccine in question. They claim that CureVac did not provide any data on the number of patients in its efficacy trial who developed acute illness. Other vaccines continue to prevent most hospitalizations and deaths, even when variants reduce their protection against mild COVID-19.

Additionally, the report indicates that the type of mRNA used by CureVac may impair antibody formation. Another factor the researchers pointed to is the very low vaccine dose. Either way, CureVac says it should wait for the final review of the current efficacy test before making a “strategic change.”

See also  Health system overload expected to be intensified by microns, says doctor

But what does Bill Gates have to do with the vaccine?

What is the relationship, after all, between the former Microsoft CEO and CureVac? The German vaccine was funded by the Bill & Melinda Gates Foundation, in addition to signing an agreement to manufacture it at the Tesla plant in Elon Musk. In addition to the two names, CureVac has also received funding from billionaire Dietmar Hopp, co-founder of SAP, a software giant.

Source: Science

Did you like this article?

Subscribe to your Canaltech email to receive daily updates with the latest news from the world of technology.

Ursula Curtis

“Writer. Analyst. Avid travel maven. Devoted twitter guru. Unapologetic pop culture expert. General zombie enthusiast.”

Ursula Curtis

Ursula Curtis

"Writer. Analyst. Avid travel maven. Devoted twitter guru. Unapologetic pop culture expert. General zombie enthusiast."

Next Post
Jessica Athead sighs: "Oh, desperation."

Jessica Athead sighs: "Oh, desperation."

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Navigate

  • Home
  • Top News
  • World
  • Economy
  • science
  • Technology
  • sport
  • entertainment
  • Contact Form

Pages

  • About Us
  • Privacy Policy
  • DMCA
  • Editorial Policy
  • Contact Form
  • About Us
  • Privacy Policy
  • DMCA
  • Editorial Policy
  • Contact Form

© 2022 JNews - Premium WordPress news & magazine theme by Jegtheme.

No Result
View All Result
  • About Us
  • Contact Form
  • DMCA
  • Editorial Policy
  • Privacy Policy

© 2022 JNews - Premium WordPress news & magazine theme by Jegtheme.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In